Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Pre-menopausal women, 18-50 years, inclusive.~* Cyclic abnormal uterine bleeding (heavy or prolonged).~* Menstrual blood loss (MBL) of ≥ 80 mL as measured by the alkaline hematin method in the first 8 days of menses.~* Minimum of one discrete leiomyoma observable by transvaginal ultrasound.~* Endometrial biopsy without evidence of malignancy or atypical or non-atypical hyperplasia~Exclusion Criteria:~* History of uterine surgery that would interfere with the study endpoints.~* Known coagulation disorder including bleeding disorder or clotting disorder.~* History of, or current uterine, cervix, ovarian, or breast cancer.~* Alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), or total bilirubin two times or greater than the upper limit of normal rang

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- UPA 5 mg (Type: EXPERIMENTAL): Ulipristal acetate (UPA) 5 mg tablet plus matching placebo 10 mg tablet, orally, once daily for 12 weeks.
- UPA 10 mg (Type: EXPERIMENTAL): UPA 10 mg tablet plus matching placebo 5 mg tablet, orally, once daily for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablets (5 mg and 10 mg), orally, once daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).